[Clinical problems in gemcitabine treatment for unresectable pancreatic cancer in the elderly--a multicentric retrospective study of 53 cases].
In Gemcitabine treatment, elderly patients with unresectable pancreatic cancer are more likely to suffer from haematological and non-haematological adverse effects than non-elderly patients. Forty percent of the elderly patients were dropped from the initial protocol due to the adverse effects, mainly because of non-haematological events or symptoms. To avoid adverse effects, the administration schedule for Gemcitabine tended to be less often and at a lower dose for elderly patients among members of the Nagano Pancreatic Cancer Study Group. However, the fact that some cases showed a limited effect from this administration schedule albeit without adverse effect, might suggest that the frequency of ordinary administration schedule should be maintained, although the Gemcitabine dose could be decreased in unresectable pancreatic cancer patients in poor condition.
Takeuchi
Nobumichi
N
Dept of Surgery, Ina Central Hospital.
Maejima
Shinya
S
Hasebe
Osamu
O
Matsuda
Yoshiaki
Y
Hanazaki
Kazuhiro
K
Kajikawa
Shoji
S
Mukawa
Kenji
K
Hosokawa
Koichi
K
Hayashi
Ken
K
Hisa
Takeshi
T
Furut
Kiyoshi
K
Tajiri
Kazuo
K
Fujimori
Yoshiro
Y
Kaneko
Gengo
G
Ochi
Yasuhide
Y
Shikama
Naoto
N
Kawa
Shigeyuki
S
Miyagawa
Shinichi
S
Miwa
Shiro
S
Kiyosawa
Kendo
K
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine